SymBio Pharmaceuticals
Company
SymBio Pharmaceuticals develops one asset, approved (brincidofovir in smallpox). Mostly small molecule.
- 1
- Asset
- Furthest stage
- Approved
- 8
- Trials
- 0
- Signals
Pipeline
1A lipid-conjugated cidofovir prodrug that inhibits viral DNA polymerase, blocking viral DNA replication.
Approved, Small molecule, smallpox, Partner
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Trials8
- Similar companies1